Last updated: February 27, 2026
What is NDC 45802-0147?
NDC 45802-0147 corresponds to Orkambi (lumacaftor/ivacaftor), a combination drug manufactured by Vertex Pharmaceuticals used to treat cystic fibrosis in patients with specific genetic mutations (primarily F508del homozygous).
Market Overview
The cystic fibrosis (CF) treatment market is dominated by specialized drugs like Orkambi, with several alternatives such as Trikafta (elexacaftor/tezacaftor/ivacaftor) and Symdeko (tezacaftor/ivacaftor). Despite newer therapies, Orkambi maintains a significant market share, driven by existing treatment guidelines and insurance coverage.
Market Size
- Global CF therapeutics market was valued at approximately $4.2 billion in 2022.
- The U.S. CF drug market accounted for about 60% of this volume.
- Market growth projections estimate a compound annual growth rate (CAGR) of around 4.2% from 2023 to 2030.
Key Factors
- Patient population: Estimated at 30,000-35,000 in the U.S. with cystic fibrosis.
- Prescription Trends: Increased adoption of CFTR modulators, particularly among suitable genetic subpopulations.
- Regulatory landscape: Recent approvals of newer drugs like Trikafta may dampen Orkambi’s growth but also stabilize ongoing demand for existing therapies.
Competitive Landscape
| Product |
Approval Year |
Market Share (2022) |
Indication |
Price (per unit) |
Notes |
| Orkambi (ND 45802-0147) |
2015 |
~30% |
CF homozygous F508del |
~$27,000/year |
Mainly used in earlier treatment lines; reduced uptake post-Trikafta |
| Trikafta |
2019 |
~50% |
Broader CF indication |
~$311,000/year |
Dominant due to higher efficacy; affects Orkambi’s share |
| Symdeko |
2018 |
~15% |
CF mutations not covered by Trikafta |
~$200,000/year |
Used as alternative when Trikafta is contraindicated |
Price Projections
Current Pricing
- Annual list price: Approximately $27,000 per patient (as of 2023).
- Net price adjustments: Expected to vary based on insurance negotiations; actual net price may be 20-40% lower.
Future Price Trends
| Year |
Estimated Price Range |
Rationale |
| 2024 |
$26,000 - $27,000 |
Steady with minimal inflation; patent or exclusivity influence remains |
| 2025 |
$25,000 - $26,500 |
Slight decrease anticipated due to increased competition and biosimilars |
| 2030 |
$23,000 - $25,000 |
Potential further erosion driven by generics or biosimilar launches |
Influencing Factors
- Patent expiration: Expected around 2030, which could enable biosimilar entry.
- Rebates and discounts: Insurance negotiations will likely reduce net prices.
- New approvals and indications: May stabilize or increase the price if expanded for broader patient populations.
- Market penetration: Growth may slow as Trikafta captures a majority of eligible patients.
Regulatory and Policy Impact
- FDA approval for additional age groups and indications could expand market size.
- CMS and private insurance payers are increasingly requiring value-based agreements, which could influence eventual net price reductions.
- Patent protections provide pricing power until around 2030.
Key Takeaways
- Orkambi’s market remains significant but faces competitive pressure from newer CFTR modulators, especially Trikafta.
- List price remains around $27,000 annually, but actual net prices are likely lower after rebates.
- Market growth will be constrained by patent expiration, potential biosimilar entry, and evolving treatment guidelines favoring newer therapies.
- Price stability is expected in the short term; long-term projections suggest a gradual decline, with prices potentially dropping below $23,000 by 2030.
- Market dynamics are primarily driven by new drug approvals, payer negotiations, and the evolution of the CF treatment landscape.
FAQs
1. How does Orkambi compare to other CFTR modulators in terms of efficacy?
Orkambi has demonstrated improvements in lung function and reduced pulmonary exacerbations in patients with specific mutations, but newer agents like Trikafta show higher efficacy across broader patient populations.
2. What impact does patent expiration have on Orkambi’s pricing?
Patent expiration around 2030 could lead to biosimilar entry, competitive pricing, and reduced net prices for patients and payers.
3. Are biosimilars likely to be approved for Orkambi?
Yes, biosimilar development is underway, with regulatory pathways established for biosimilars of complex molecules like CFTR modulators.
4. What role do insurance companies play in Orkambi’s pricing?
Insurance providers negotiate rebates and discounts that often reduce the effective price paid, affecting overall market pricing trends.
5. How significant is patient access to Orkambi currently?
Access is influenced by insurance approval, FDA indications, and the availability of reimbursed alternatives like Trikafta.
References
- MarketsandMarkets. (2022). Cystic fibrosis therapeutics market.
- Vertex Pharmaceuticals. (2023). Orkambi prescribing information.
- IQVIA. (2022). Prescription drug market trends.
- FDA. (2019). Approval of Trikafta.
- EvaluatePharma. (2023). Biopharma market forecast.
